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Abstract 
Introduction 
International guidelines on the primary prevention of cardiovascular disease recommend that preventive measures 
should be based on the doctors’ quantitative total risk assessment of the patient. Treatment is recommended when the 
patient’s risk is above a certain threshold. Risk scoring systems have been developed to assist clinicians with risk 
estimates. However, in clinical practice this estimation is usually made subjectively. This implies that factors unrelated 
to the true risk of the patients may influence the doctors’ risk estimates and decisions about treatment. 
Aim 
We aimed to study coronary preventive care in two areas with different coronary risk levels, with special reference to 
doctors’ attitudes in investigating risk factors, and their risk assessments and decisions about treatment. In accordance 
with the different levels of cardiovascular risk in the areas studied, we also aimed to test the hypothesis that the same set 
of risk factors may be perceived as indicating higher risk in a high-risk country, than in a low-risk country. 
Methods 
The studies were performed in two European areas, one with a high and the other with a low level of population 
cardiovascular risk, Stockholm county and Sicily, respectively. Questionnaires on doctors’ clinical practice (Study I) 
and written patient cases (Studies II-IV) were presented to random samples of doctors in Stockholm and in Sicily. The 
cases were constructed according to the Framingham scoring system, ranging from very high- to very low-risk cases. 
Differences in the use of statins and coronary mortality in the populations (Study V) were studied by collecting official 
data from the health care systems in both areas. 
Results and Discussion 
There were differences in the management of hyperlipidaemia (Study I). More doctors in Stockholm investigated lipids 
in patients with other cardiovascular risk factors. The cholesterol level at which doctors started lipid-lowering treatment 
was higher in Stockholm than in Sicily. In Study II, General Practitioners (GPs) were asked to evaluate nine written 
patient cases. Their coronary risk estimates showed large variability, especially in high-risk cases, and in general the 
risk was underestimated compared to the risk calculated according to the Framingham equations. Contrary to the 
hypothesis, GPs in Stockholm made lower estimates and less often decided to start lipid-lowering treatment than was 
the case in Sicily. A possible reason for this is that a high background risk level of the population tends to suppress the 
risk estimate of an individual with a certain set of risk factors, and vice versa if the population risk is low. Support to 
such line of thinking was found comparing risk estimates and decisions about treatment between doctors who usually 
deal with coronary preventive care: GPs, cardiologists and internists (Study III). Compared to the other specialists, 
cardiologists, who usually deal with high-risk patients, showed lower risk estimates when assessing the same set of 
patient cases. In study IV we found that the task of risk rating and the task of making decisions about treatment did not 
mutually influence each other. Female GPs and GPs with shorter clinical experience were more likely to make correct 
decisions. 
The differences in coronary risk ratings and decisions about treatment observed in the two areas with different 
population coronary risk levels may be related to the use of statins in the whole population of the respective area. Study 
V investigated the time trends in the relations between population coronary risk levels, expressed as coronary mortality, 
and use of statins, in the period 2001-2011. In both areas there was a reduction in coronary mortality and an increase in 
statin utilization. A larger reduction in coronary mortality was observed in Stockholm compared to Sicily, whereas the 
statin utilization increased more in Sicily than in Stockholm. Thus, the changes over time in statin utilization seem 
inversely associated with the changes in coronary mortality. However, the influence of other variables that are 
independent of the population coronary risk, such as cost containment policies, socioeconomic gradients in the use of 
statins, and drug discontinuation rate, must be taken into account. 
Conclusions 
There are several differences in primary coronary prevention between the two European areas with different population 
cardiovascular risk profiles. Doctors’ quantitative risk estimates and decisions about treatment are influenced by factors 
not directly related to the actual risk of the patients, and seem tentatively to be inversely related to the background 
cardiovascular risk in the population. The differences in primary coronary prevention may contribute to an increase in 
statin utilization that is not justified by changes in population coronary risk. The results of the thesis may help in the 
development of decision tools and recommendations for primary coronary prevention. 
